EGFR and non-small cell lung carcinoma: To investigate the effect of acquired resistance on PD-L1 expression in NSCLC, HCC827 (EGFR Del 19), which is sensitive to TKIs therapy, was exposed to Gefitinib (2 μM) for more than 6 months.